IL312041A - R-ketamine salts and methods of using them - Google Patents

R-ketamine salts and methods of using them

Info

Publication number
IL312041A
IL312041A IL312041A IL31204124A IL312041A IL 312041 A IL312041 A IL 312041A IL 312041 A IL312041 A IL 312041A IL 31204124 A IL31204124 A IL 31204124A IL 312041 A IL312041 A IL 312041A
Authority
IL
Israel
Prior art keywords
ketamine
salts
methods
ketamine salts
Prior art date
Application number
IL312041A
Other languages
English (en)
Hebrew (he)
Inventor
Mouhannad Jumaa
Terence Alfred Kelly
Original Assignee
Perception Neuroscience Inc
Mouhannad Jumaa
Terence Alfred Kelly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perception Neuroscience Inc, Mouhannad Jumaa, Terence Alfred Kelly filed Critical Perception Neuroscience Inc
Publication of IL312041A publication Critical patent/IL312041A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255Tartaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL312041A 2021-10-12 2022-10-12 R-ketamine salts and methods of using them IL312041A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163254878P 2021-10-12 2021-10-12
PCT/US2022/046412 WO2023064363A1 (en) 2021-10-12 2022-10-12 R-ketamine salts and methods of use thereof

Publications (1)

Publication Number Publication Date
IL312041A true IL312041A (en) 2024-06-01

Family

ID=84331621

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312041A IL312041A (en) 2021-10-12 2022-10-12 R-ketamine salts and methods of using them

Country Status (8)

Country Link
US (1) US20240336556A1 (https=)
EP (1) EP4416126A1 (https=)
JP (1) JP2024539623A (https=)
CN (1) CN118647595A (https=)
CA (1) CA3234818A1 (https=)
IL (1) IL312041A (https=)
MX (1) MX2024004478A (https=)
WO (1) WO2023064363A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
CN119613277A (zh) * 2023-09-14 2025-03-14 江苏恩华药业股份有限公司 一种(r)-氯胺酮d-酒石酸盐e晶型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338680A1 (en) 2001-09-21 2003-04-07 Solvias Ag Sealing system with flow channels
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
US20200405663A1 (en) 2017-09-27 2020-12-31 National University Corporation Chiba University R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2020138491A1 (ja) 2018-12-27 2020-07-02 国立大学法人千葉大学 神経発達障害の予防または治療剤としてのr-ケタミンおよびその誘導体

Also Published As

Publication number Publication date
CA3234818A1 (en) 2023-04-20
MX2024004478A (es) 2024-07-01
EP4416126A1 (en) 2024-08-21
US20240336556A1 (en) 2024-10-10
WO2023064363A9 (en) 2024-02-15
JP2024539623A (ja) 2024-10-29
WO2023064363A1 (en) 2023-04-20
CN118647595A (zh) 2024-09-13

Similar Documents

Publication Publication Date Title
IL304680A (en) Urolithin history and methods of using them
SI3966207T1 (sl) Fenilaminopirimidinamidni zaviralci avtofagije in načini njihove uporabe
SG11202112171XA (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
SG11202107614PA (en) Pcsk9 inhibitors and methods of use thereof
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
SG11202107615TA (en) Pcsk9 inhibitors and methods of use thereof
IL287973A (en) acss2 inhibitors and methods of their use
IL279475A (en) Actonucleotidase inhibitors and methods of using them
ZA202407941B (en) Arginase inhibitors and methods of use thereof
PT4185580T (pt) Formas de estado sólido de belumosudil e sais de belumosudil
IL299245A (en) LAIR-1 binding agents and methods of using them
IL280924A (en) Arginase inhibitors and methods of using them
GB2613900B (en) Novel compounds and methods of use thereof
IL312041A (en) R-ketamine salts and methods of using them
IL312261A (en) Novovirus vaccine and methods of use
IL307752A (en) Intracardiac device and methods of use
IL295228B2 (en) A method for the production of dalmofinol and its salts
IL277528B (en) Herbicidal compounds and methods of their use
GB201811737D0 (en) Forceps and method of manufacture and use
GB202119051D0 (en) Wingsail and method of use
HK40114491A (en) R-ketamine salts and methods of use thereof
SG11202011549RA (en) Topical formulations of dgat1 inhibitors and their methods of use
GB202004360D0 (en) Compounds and methods of use
IL290548A (en) Bacteria and methods of using them